Spots Global Cancer Trial Database for Camrelizumab Utilization on Patients With Advanced Liver Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Camrelizumab Utilization on Patients With Advanced Liver Cancer

Official Title: A Real World Study of Treatment Regimens Containing Camrelizumab in Patients With Advanced Liver Cancer

Study ID: NCT04487704

Conditions

Advanced Hepatocellular Carcinoma

Interventions

camrelizumab

Study Description

Brief Summary: To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer

Detailed Description: camrelizumab ， a humanized monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1, thereby inhibiting the immune escape of tumor cells. It has a high affinity for PD-1 (KD = 3.31 nmol/L), a high acceptor proportion (85% at 200 mg) of circulating T lymphocytes, and binds to epitopes different from Nivolumab and pembrolizumab，Phase 1 clinical trials have shown that camrelizumab is well tolerated and has antitumor activity in patients with advanced solid tumors.camrelizumab has been approved for indication for advanced hepatocellular carcinoma The main objective of this study was to observe and evaluate the safety and efficacy of treatment regiments containing Camrelizumab in advanced liver cancer。 The subjects included people over 18 years old， For men and women with advanced liver cancer confirmed by histopathology or cytology;